SCHEMBL3019990

SCHEMBL3019990

O=S(=O)(c1ccccc1Br)N1CCN(c2nc(-c3ccccc3)cs2)CC1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.67
MAPK1 P28482 3/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
SMN1; SMN2 Q16637 4/20 0.62
ALDH1A1 P00352 3/20 0.62
MAPT P10636 3/20 0.62
L3MBTL1 Q9Y468 2/20 0.57
GBA1 P04062 2/20 0.55
AR P10275 3/20 0.55
HSD17B10 Q99714 3/20 0.55
TP53 P04637 2/20 0.55
ALOX15 P16050 1/20 0.55
RAB9A P51151 6/20 0.54
NPC1 O15118 4/20 0.52
HTT P42858 1/20 0.52
NPSR1 Q6W5P4 1/20 0.51
USP2 O75604 1/20 0.48
RECQL P46063 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008092 0.91 SMN1; SMN2 (0.76) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3012669 0.91 MAPT (0.61) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3011596 0.91 SMN1; SMN2 (0.61) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3018650 0.90 LMNA (0.57) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3003616 0.88 MAPT (0.56) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3015062 0.88 MAPT (0.58) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3010909 0.88 LMNA (0.61) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3017812 0.88 SMN1; SMN2 (0.55) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3021705 0.88 SMN1; SMN2 (0.63) LMNAMAPK1MEN1KMT2ASMN1; SMN2
SCHEMBL3013262 0.88 SMN1; SMN2 (0.55) LMNAMAPK1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPK1 2767/4885MEN1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.